Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBlue Cross NC Omisirge IV Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Omidubicel-onlv (Omisirge) — medical necessity and coverage criteria for intravenous infusion

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs medical necessity coverage and administrative requirements for omidubicel-onlv (Omisirge) IV infusion for eligible patients receiving umbilical cord blood transplantation or with severe aplastic anemia, affecting providers and prior authorization for Blue Cross NC members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyOmidubicel-onlv (Omisirge) — coverage criteria for IV infusion
    Policy CodePolicy N/A
    Change TypeCoding update and policy notification
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit medical record documentation demonstrating indication, age, conditioning regimen, donor availability, and requested dose within FDA labeling.
    SourceLink
    POLICY UPDATE CHANGES

    Added applicable revenue codes 0891 and 0892 associated with policy HCPCS code(s).

    Original medical policy criteria issued and policy put on notice for effective date April 1, 2026.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 year
    Duration of approval (maximum)
    one-timeDose frequency per lifetime
    C9399Applicable HCPCS codes
    0891, 0892Added revenue codes
    ≥12 / ≥6FDA age indications (HM / SAA)

    Medical Necessity and Coverage Criteria

    Medical necessity criteria (Initial/One-time dosing)

    Covered when ALL of the following group-specific criteria are met (distinct branches for hematologic malignancy with planned UCBT and severe aplastic anemia):

    Indication branch: Either Branch A (hematologic malignancy with planned UCBT) OR Branch B (severe aplastic anemia) must be met

    Two distinct indication pathways

    Branch A: Hematologic malignancy with planned UCBT: 1) The patient has a diagnosis of a high-risk hematologic malignancy (e.g., AML, ALL, MDS, NHL, myeloproliferative diseases) [medical record documentation required]; AND 2) The patient is 12 years of age or older; AND 3) The patient is planned for an umbilical cord blood transplantation (UCBT) following myeloablative conditioning [medical record documentation required]; AND 4) The requested agent will be used to reduce the time to neutrophil recovery and incidence of infection [medical record documentation required]; AND 5) Prior to treatment the patient will receive a myeloablative conditioning regimen according to institutional guidelines [medical record documentation required]; AND 6) The patient is eligible for myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) and has NOT received a prior allo-HSCT [medical record documentation required]; AND 7) The patient will receive prophylactic and supportive therapies (including G-CSF) per institutional guidelines [medical record documentation required]; AND 8) The patient does NOT have any contraindications to the requested agent (e.g., known hypersensitivity to DMSO, Dextran 40, gentamicin, human serum albumin, or bovine material) [medical record documentation required]; AND 9) The prescriber is a specialist in the area of the patient's diagnosis (hematologist, oncologist) or has consulted with such a specialist [medical record documentation required]; AND 10) The requested dose is within FDA labeled dosing for the requested indication and the requested quantity does NOT exceed the maximum units allowed; Duration of approval: 365 days; one-time, single-dose per lifetime

    All subcriteria require medical record documentation

    Branch B: Severe aplastic anemia (SAA): 1) The patient has a diagnosis of severe aplastic anemia (SAA) [medical record documentation required]; AND 2) The patient is 6 years of age or older; AND 3) Diagnosis confirmed by ALL of the following: ONE of the following bone marrow criteria: (i) bone marrow cellularity less than 25% OR (ii) bone marrow cellularity 25-50% with less than 30% residual hematopoietic cells; AND presence of at least TWO of the following: neutrophils less than 0.5 x 10^9/L OR platelets less than 20 x 10^9/L; AND reticulocytes less than 60 x 10^9/L [medical record documentation required]; AND 4) ONE of the following: (i) inadequate response to a standard immunosuppressive therapy regimen (horse antithymocyte globulin [hATG] + cyclosporine + eltrombopag) for at least 3 months [medical record documentation required] OR (ii) clinical intolerance/contraindication to ALL immunosuppressive therapy regimens [medical record documentation required]; AND 5) Prior to treatment the patient will receive a reduced intensity conditioning regimen according to institutional guidelines [medical record documentation required]; AND 6) The patient has NO readily available matched related donor (MRD), matched unrelated donor (MUD), mismatched (7/8 matched) unrelated donor (MMUD), or haploidentical related donor [medical record documentation required]; AND 7) The patient will receive prophylactic and supportive therapies (including G-CSF) per institutional guidelines [medical record documentation required]; AND 8) The patient does NOT have any contraindications to the requested agent (e.g., known hypersensitivity to DMSO, Dextran 40, gentamicin, human serum albumin, or bovine material) [medical record documentation required]; AND 9) The prescriber is a specialist in the area of the patient's diagnosis (hematologist, oncologist) or has consulted with such a specialist [medical record documentation required]; AND 10) The requested dose is within FDA labeled dosing for the requested indication and the requested quantity does NOT exceed the maximum units allowed; Duration of approval: 365 days; one-time, single-dose per lifetime

    All subcriteria require medical record documentation

    Coverage is intended for patients who do NOT have a readily available donor option. Specifically, omidubicel-onlv (Omisirge) is covered only when the patient has no readily available matched related donor (MRD), matched unrelated donor (MUD), mismatched (7/8 matched) unrelated donor (MMUD), or haploidentical related donor. Documented evaluation of donor availability must be provided in the medical record prior to authorization.

    Use of omidubicel-onlv is contraindicated in patients with known hypersensitivity to components of the product. Documented hypersensitivity to any of the following excludes coverage: dimethyl sulfoxide (DMSO), Dextran 40, gentamicin, human serum albumin, or bovine material.

    Dosing, Regimen Limits, and Approval Duration

    RegimenDose / Cell count requirementsMaximum unitsDuration of approval
    One-time, single-dose intravenous (IV) infusion of omidubicel-onlv (Omisirge) per FDA label; indicated to reduce time to neutrophil recovery and incidence of infection following myeloablative conditioning in patients ≥12 years planned for umbilical cord blood transplantation; also indicated for severe aplastic anemia in patients ≥6 years following reduced-intensity conditioning.
    Cultured Fraction (CF): minimum of 8.0 x 10^8 total viable cells (of which ≥8.7% are CD34+ and ≥9.2 x 10^7 CD34+ cells). Non-cultured Fraction (NF): minimum of 4.0 x 10^8 total viable cells (with ≥2.4 x 10^7 CD3+ cells). Requested dose must be within FDA labeled dosing.
    1
    365 days (1 year); one-time, single-dose treatment per lifetime

    Indication Line and Salvage Use

    Salvage

    Salvage use context: Used in patients planned for umbilical cord blood transplantation following myeloablative conditioning to reduce time to neutrophil recovery and incidence of infection (context: salvage-line use tied to transplant plan rather than a specific prior-line count).

    Medical record documentation of planned UCBT and conditioning required

    HCPCS, Revenue Codes, and Product Specifications

    Applicable HCPCS/Codes listedHCPCS
    C9399Unclassified drugs or biologicals
    J3490Unclassified drugs
    J3590Unclassified biologics
    J9999Not otherwise classified code
    Applicable revenue codesRevenue
    0891Special Processed Drugs - FDA Approved Cell Therapy (revenue code)
    0892Special Processed Drugs - FDA Approved Gene Therapy (revenue code)
    inv-06: Cultured Fraction minimum total viable cells and CD34+ thresholds (CF)
    Minimum total viable cells (CF)≥ 8.0 × 10^8 total viable cells
    Minimum percent CD34+ (CF)≥ 8.7% of CF total viable cells
    Minimum absolute CD34+ cells (CF)≥ 9.2 × 10^7 CD34+ cells
    inv-07: Non-cultured Fraction minimum total viable cells and CD3+ thresholds (NF)
    Minimum total viable cells (NF)≥ 4.0 × 10^8 total viable cells
    Minimum absolute CD3+ cells (NF)≥ 2.4 × 10^7 CD3+ cells

    Prior Authorization, Documentation, and Billing Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit medical necessity documentation with the prior authorization request. Requests that do not include required medical record documentation (see items below) may be denied.

    • Required documentation must be submitted with the prior authorization request: diagnosis, patient age, planned transplantation type (e.g., UCBT) and conditioning regimen (myeloablative or reduced-intensity), intent to reduce neutrophil recovery time and incidence of infection (when applicable), prior allo-HSCT history, details confirming lack of readily available matched donor (MRD/MUD/MMUD/haploidentical) when applicable, confirmation of prior SAA therapy (e.g., hATG + cyclosporine + eltrombopag) or contraindication to immunosuppressive therapy for SAA, eligibility for myeloablative allo-HSCT (for hematologic malignancy indication), planned prophylactic/supportive therapies (including G-CSF), prescriber specialty or consultation with a specialist, documentation of dosing within FDA-labeled limits and requested quantity, and documentation of any contraindications (e.g., known hypersensitivity to DMSO, Dextran 40, gentamicin, human serum albumin, or bovine material).
    • Documentation examples: operative/transplantation plan, clinic notes, pathology or marrow reports (e.g., bone marrow cellularity, reticulocyte count), prior treatment records showing trial and inadequate response to standard immunosuppressive therapy for SAA, allergy/intolerance documentation, and institutional conditioning regimen orders.

    Product Fraction Definitions

    inv-13: Cultured Fraction (CF) definition and numeric thresholds
    Definition (CF)Cultured Fraction (CF) of omidubicel-onlv; portion of the product that has been ex vivo cultured prior to infusion
    Minimum total viable cells≥ 8.0 × 10^8 total viable cells
    CD34+ content requirements≥ 8.7% CD34+ cells and ≥ 9.2 × 10^7 CD34+ cells
    inv-14: Non-cultured Fraction (NF) definition and numeric thresholds
    Definition (NF)Non‑cultured Fraction (NF) of omidubicel-onlv; portion of the product that is not cultured prior to infusion
    Minimum total viable cells≥ 4.0 × 10^8 total viable cells

    Clinical Background and Product Description

    Omidubicel-onlv (Omisirge) is an FDA-approved, one-time, single-dose umbilical cord blood–derived product composed of cultured and non‑cultured fractions intended to reduce time to neutrophil recovery and incidence of infection in patients undergoing umbilical cord blood transplantation or to treat severe aplastic anemia following appropriate conditioning. Coverage is for a single intravenous infusion per lifetime when medical necessity criteria and dosing within the FDA label are met; documentation of diagnosis, planned conditioning/transplant intent, and prescribed dose are required.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyOmidubicel-onlv (Omisirge) — coverage criteria for IV infusion
    Policy CodePolicy N/A
    Change TypeCoding update and policy notification
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit medical record documentation demonstrating indication, age, conditioning regimen, donor availability, and requested dose within FDA labeling.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaDosing, Regimen Limits, and Approval DurationIndication Line and Salvage UseHCPCS, Revenue Codes, and Product SpecificationsPrior Authorization, Documentation, and Billing RequirementsProduct Fraction DefinitionsClinical Background and Product Description
    Documentation Required

    Documentation Required

    Medical record documentation is required and must be submitted with the request. Failure to provide the required records may result in denial of coverage.

    • At minimum include: diagnosis and supporting clinical data (e.g., marrow cellularity, reticulocyte count), patient age, planned transplant type and conditioning intensity, documentation that the requested product will be used to reduce time to neutrophil recovery and infection (for UCBT indication), prior allo-HSCT status, lack of suitable donors (when applicable), prior SAA therapy and response (e.g., hATG + cyclosporine + eltrombopag) or contraindication to immunosuppression, prophylactic/supportive care plan (including G-CSF), prescriber specialty or consult, dosing and quantity justification within FDA limits, and any contraindication documentation.
    Denial Risk

    Denial Risk — Missing Medical Record Documentation

    Requests missing any of the required medical records or lacking documentation to support key eligibility criteria (diagnosis, planned UCBT/myeloablative or reduced-intensity conditioning, prior allo‑HSCT details, prior SAA therapy and response or contraindication, lack of suitable donors, or prescriber specialty/consultation) are at risk for denial.

    • Common denial-risk omissions: absent marrow reports (cellularity), missing reticulocyte counts, no documentation of prior standard immunosuppressive therapy trial and inadequate response for SAA, no transplant plan or conditioning regimen documentation, and no documentation confirming absence of suitable donors.
    CD3+ content requirement
    ≥ 2.4 × 10^7 CD3+ cells